letrozole has been researched along with Disease Exacerbation in 54 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor-positive (HR+) tumours." | 9.30 | Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. ( Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V, 2019) |
| "A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months." | 9.20 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. ( Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND, 2015) |
| "Goserelin and letrozole in premenopausal patients can result in clinical outcomes comparable to those obtained by letrozole alone in postmenopausal patients with metastatic breast cancer (MBC)." | 9.14 | Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. ( Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J, 2010) |
| "To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC)." | 9.12 | Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. ( Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB, 2007) |
| "Tamoxifen has been a standard first-line endocrine therapy for post-menopausal women with hormone-responsive advanced breast cancer, but more than half of patients fail to respond and time to progression is less than 12 months in responders." | 9.12 | Letrozole in advanced breast cancer: the PO25 trial. ( Mouridsen, HT, 2007) |
| "To compare the efficacy, in regard to time to progression (TTP) and objective response rate (ORR), of letrozole (Femara; Novartis Pharma AG; Basel Switzerland), an oral aromatase inhibitor, with that of tamoxifen (Tamofen; Leiras OY; Turku, Finland) as first-line therapy in younger (<70 years) and older (>/=70 years) postmenopausal women with advanced breast cancer." | 9.11 | Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. ( Chaudri-Ross, HA; Mouridsen, H, 2004) |
| "To evaluate the clinical benefit and tolerability of letrozole after tamoxifen failure in locally advanced, recurrent or metastatic breast cancer in postmenopausal patients." | 9.11 | Efficacy of letrozole for advanced breast cancer in postmenopausal patients. ( Ansari, TN; Hussain, I; Mahmood, A; Samad, A, 2005) |
| "0 mg once daily to be more effective in treating postmenopausal women with advanced breast cancer than fadrozole at 1." | 9.10 | Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. ( Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T, 2003) |
| "ER+, ErbB-1+, and/or ErbB-2+ primary breast cancer responded well to letrozole, but responses to tamoxifen were infrequent." | 9.09 | Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. ( Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B, 2001) |
| "Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2." | 9.08 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. ( Bellmunt, J; Bezwoda, W; Chaudri, HA; Dombernowsky, P; Falkson, G; Fornasiero, A; Gardin, G; Gudgeon, A; Hatschek, T; Hoffmann, W; Hornberger, U; Leonard, R; Michel, J; Morgan, M; Panasci, L; Smith, I; Tjabbes, T; Trunet, PF, 1998) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 9.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen." | 8.88 | Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). ( Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R, 2012) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 7.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 7.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| " We evaluated the efficacy of the aromatase inhibitor letrozole in patients with metastatic breast cancer (MBC) as related to DNA polymorphisms of CYP19A1." | 7.77 | Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. ( Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J, 2011) |
| "4%), who have participated in the international, randomized, phase III clinical trial PO25 comparing letrozole with tamoxifen in 907 patients with advanced breast cancer." | 7.75 | An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. ( Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB, 2009) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure." | 7.73 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. ( Alba, E; Barnadas, A; Carabante, F; Colomer, R; Fernández, R; Gil, M; González, J; Llombart, A; Mayordomo, JI; Palomero, I; Ramos, M; Ribelles, N; Ruiz, M; Soriano, V; Tusquets, I; Vera, R, 2006) |
| "For postmenopausal women with early breast cancer who have completed 5 years of adjuvant tamoxifen, the cost-effectiveness of extended adjuvant letrozole is within the range of other generally accepted medical interventions in the United States." | 7.73 | Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. ( Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC, 2006) |
| "To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer." | 7.72 | Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L, 2004) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 7.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "Slow disease progression after a poor response to adriamycin and hormone receptor positivity led to the start of letrozole." | 5.91 | Long-term effect of letrozole on metastatic uterine smooth muscle tumors of uncertain malignant potential: A case report. ( Hayashi, T; Kato, S; Kido, H; Naito, T; Praben, P; Takagi, T; Terao, Y, 2023) |
| "Women with breast cancer and diabetes mellitus (DM) have poorer survival." | 5.43 | Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. ( Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D, 2016) |
| "The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor-positive (HR+) tumours." | 5.30 | Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. ( Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V, 2019) |
| "A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months." | 5.20 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. ( Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND, 2015) |
| "Goserelin and letrozole in premenopausal patients can result in clinical outcomes comparable to those obtained by letrozole alone in postmenopausal patients with metastatic breast cancer (MBC)." | 5.14 | Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. ( Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J, 2010) |
| "Tamoxifen has been a standard first-line endocrine therapy for post-menopausal women with hormone-responsive advanced breast cancer, but more than half of patients fail to respond and time to progression is less than 12 months in responders." | 5.12 | Letrozole in advanced breast cancer: the PO25 trial. ( Mouridsen, HT, 2007) |
| "To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC)." | 5.12 | Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. ( Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB, 2007) |
| "To evaluate the clinical benefit and tolerability of letrozole after tamoxifen failure in locally advanced, recurrent or metastatic breast cancer in postmenopausal patients." | 5.11 | Efficacy of letrozole for advanced breast cancer in postmenopausal patients. ( Ansari, TN; Hussain, I; Mahmood, A; Samad, A, 2005) |
| "To compare the efficacy, in regard to time to progression (TTP) and objective response rate (ORR), of letrozole (Femara; Novartis Pharma AG; Basel Switzerland), an oral aromatase inhibitor, with that of tamoxifen (Tamofen; Leiras OY; Turku, Finland) as first-line therapy in younger (<70 years) and older (>/=70 years) postmenopausal women with advanced breast cancer." | 5.11 | Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. ( Chaudri-Ross, HA; Mouridsen, H, 2004) |
| "This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex')." | 5.10 | Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. ( Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I, 2003) |
| "0 mg once daily to be more effective in treating postmenopausal women with advanced breast cancer than fadrozole at 1." | 5.10 | Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. ( Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T, 2003) |
| "ER+, ErbB-1+, and/or ErbB-2+ primary breast cancer responded well to letrozole, but responses to tamoxifen were infrequent." | 5.09 | Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. ( Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B, 2001) |
| "Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2." | 5.08 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. ( Bellmunt, J; Bezwoda, W; Chaudri, HA; Dombernowsky, P; Falkson, G; Fornasiero, A; Gardin, G; Gudgeon, A; Hatschek, T; Hoffmann, W; Hornberger, U; Leonard, R; Michel, J; Morgan, M; Panasci, L; Smith, I; Tjabbes, T; Trunet, PF, 1998) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 5.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen." | 4.88 | Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). ( Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R, 2012) |
| "Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen)." | 4.80 | The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. ( Hamilton, A; Piccart, M, 1999) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 3.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 3.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| " We evaluated the efficacy of the aromatase inhibitor letrozole in patients with metastatic breast cancer (MBC) as related to DNA polymorphisms of CYP19A1." | 3.77 | Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. ( Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J, 2011) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "4%), who have participated in the international, randomized, phase III clinical trial PO25 comparing letrozole with tamoxifen in 907 patients with advanced breast cancer." | 3.75 | An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. ( Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB, 2009) |
| "For postmenopausal women with early breast cancer who have completed 5 years of adjuvant tamoxifen, the cost-effectiveness of extended adjuvant letrozole is within the range of other generally accepted medical interventions in the United States." | 3.73 | Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. ( Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC, 2006) |
| "Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance." | 3.73 | Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. ( Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A, 2005) |
| "The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer." | 3.73 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. ( Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F, 2005) |
| "To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure." | 3.73 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. ( Alba, E; Barnadas, A; Carabante, F; Colomer, R; Fernández, R; Gil, M; González, J; Llombart, A; Mayordomo, JI; Palomero, I; Ramos, M; Ribelles, N; Ruiz, M; Soriano, V; Tusquets, I; Vera, R, 2006) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 3.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer." | 3.72 | Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L, 2004) |
| " This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR)." | 3.71 | Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? ( Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM, 2001) |
| "Letrozole was administered at a dose of 2." | 2.73 | Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. ( Coleman, RL; Deavers, M; Gershenson, DM; Kavanagh, JJ; Levenback, C; Milam, MR; Ramirez, PT; Schmeler, KM; Slomovitz, BM; Smith, JA, 2008) |
| "HER2-positive breast cancer accounts for 20 to 25% of breast cancers." | 2.46 | [Management of metastatic HER2-positive breast cancer: present and future]. ( Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S, 2010) |
| "Slow disease progression after a poor response to adriamycin and hormone receptor positivity led to the start of letrozole." | 1.91 | Long-term effect of letrozole on metastatic uterine smooth muscle tumors of uncertain malignant potential: A case report. ( Hayashi, T; Kato, S; Kido, H; Naito, T; Praben, P; Takagi, T; Terao, Y, 2023) |
| "Women with breast cancer and diabetes mellitus (DM) have poorer survival." | 1.43 | Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. ( Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D, 2016) |
| "In the example of an early breast cancer trial for which a new treatment significantly delayed disease recurrence, our Bayesian analysis showed that with very reasonable assumptions on the effects of treatment after recurrence, there is a high probability that the new treatment improves overall survival." | 1.43 | Assessing survival benefit when treatment delays disease progression. ( Finkelstein, DM; Schoenfeld, DA, 2016) |
| "Second, disease progression is monitored at regular clinic visits, and progression time is recorded as the first visit at which evidence of progression is detected." | 1.40 | A joint test for progression and survival with interval-censored data from a cancer clinical trial. ( Finkelstein, DM; Schoenfeld, DA, 2014) |
| "The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008." | 1.38 | Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012) |
| "All patients with breast cancer who were initially treated with PHT between January 2002 and December 2008 were identified from a single consultant's prospectively maintained database." | 1.37 | Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? ( Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E, 2011) |
| "A case of solitary bone metastasis from breast cancer, where MRI assessment of treatment response was inaccurate and whole-body fluorodeoxyglucose ((18)FDG) positron emission tomography with computed tomography (PET-CT) proved more reliable and objective, is presented." | 1.36 | Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment. ( Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.56) | 18.2507 |
| 2000's | 24 (44.44) | 29.6817 |
| 2010's | 26 (48.15) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Praben, P | 1 |
| Kido, H | 1 |
| Terao, Y | 1 |
| Takagi, T | 1 |
| Hayashi, T | 1 |
| Naito, T | 1 |
| Kato, S | 1 |
| Selli, C | 1 |
| Turnbull, AK | 1 |
| Pearce, DA | 1 |
| Li, A | 1 |
| Fernando, A | 1 |
| Wills, J | 1 |
| Renshaw, L | 2 |
| Thomas, JS | 1 |
| Dixon, JM | 2 |
| Sims, AH | 1 |
| Perrone, F | 1 |
| De Laurentiis, M | 1 |
| De Placido, S | 1 |
| Orditura, M | 1 |
| Cinieri, S | 1 |
| Riccardi, F | 1 |
| Ribecco, AS | 1 |
| Putzu, C | 1 |
| Del Mastro, L | 3 |
| Rossi, E | 1 |
| Tinessa, V | 1 |
| Mosconi, AM | 1 |
| Nuzzo, F | 1 |
| Di Rella, F | 1 |
| Gravina, A | 1 |
| Iodice, G | 1 |
| Landi, G | 1 |
| Pacilio, C | 1 |
| Forestieri, V | 1 |
| Lauria, R | 1 |
| Fabbri, A | 1 |
| Ibrahim, T | 1 |
| De Maio, E | 1 |
| Barni, S | 1 |
| Gori, S | 1 |
| Simeon, V | 1 |
| Arenare, L | 1 |
| Daniele, G | 1 |
| Piccirillo, MC | 1 |
| Normanno, N | 1 |
| de Matteis, A | 1 |
| Gallo, C | 1 |
| Liu, X | 1 |
| Qu, H | 1 |
| Cao, W | 1 |
| Wang, Y | 1 |
| Ma, Z | 1 |
| Li, F | 1 |
| Wang, H | 1 |
| Nicolini, A | 1 |
| Rossi, G | 1 |
| Ferrari, P | 1 |
| Carpi, A | 1 |
| Finkelstein, DM | 2 |
| Schoenfeld, DA | 2 |
| Lewis, L | 1 |
| Taylor, M | 1 |
| Suriya Ertugyrovna, Y | 1 |
| Kuanysh Shadybayevich, N | 1 |
| Kaldygul Kabakovna, S | 1 |
| Ramil Zufarovich, A | 1 |
| Zhao, Y | 1 |
| Gong, P | 1 |
| Chen, Y | 1 |
| Nwachukwu, JC | 1 |
| Srinivasan, S | 1 |
| Ko, C | 1 |
| Bagchi, MK | 1 |
| Taylor, RN | 1 |
| Korach, KS | 1 |
| Nettles, KW | 1 |
| Katzenellenbogen, JA | 1 |
| Katzenellenbogen, BS | 1 |
| Wagner-Johnston, ND | 1 |
| Sloan, JA | 1 |
| Liu, H | 1 |
| Kearns, AE | 1 |
| Hines, SL | 1 |
| Puttabasavaiah, S | 1 |
| Dakhil, SR | 1 |
| Lafky, JM | 1 |
| Perez, EA | 1 |
| Loprinzi, CL | 1 |
| van Meurs, HS | 1 |
| van der Velden, J | 1 |
| Buist, MR | 1 |
| van Driel, WJ | 1 |
| Kenter, GG | 1 |
| van Lonkhuijzen, LR | 1 |
| Shankar, A | 1 |
| Roy, S | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Kamal, VK | 1 |
| Malik, A | 1 |
| Patil, J | 1 |
| Jeyaraj, PA | 1 |
| Mahajan, MK | 1 |
| Beauchemin, C | 1 |
| Letarte, N | 1 |
| Mathurin, K | 1 |
| Yelle, L | 1 |
| Lachaine, J | 1 |
| Goodwin, RA | 1 |
| Jamal, R | 1 |
| Booth, CM | 1 |
| Goss, PE | 1 |
| Eisenhauer, EA | 1 |
| Tu, D | 1 |
| Shepherd, LE | 1 |
| Burki, TK | 1 |
| Wright, LE | 1 |
| Harhash, AA | 1 |
| Kozlow, WM | 1 |
| Waning, DL | 1 |
| Regan, JN | 1 |
| She, Y | 1 |
| John, SK | 1 |
| Murthy, S | 1 |
| Niewolna, M | 1 |
| Marks, AR | 1 |
| Mohammad, KS | 1 |
| Guise, TA | 1 |
| Gershenson, DM | 2 |
| Bodurka, DC | 1 |
| Coleman, RL | 2 |
| Lu, KH | 1 |
| Malpica, A | 1 |
| Sun, CC | 1 |
| Metro, G | 1 |
| Mottolese, M | 1 |
| Fabi, A | 2 |
| Henriksen, KL | 1 |
| Rasmussen, BB | 1 |
| Lykkesfeldt, AE | 1 |
| Møller, S | 1 |
| Ejlertsen, B | 1 |
| Mouridsen, HT | 2 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Garcia-Casado, Z | 1 |
| Guerrero-Zotano, A | 1 |
| Llombart-Cussac, A | 1 |
| Calatrava, A | 1 |
| Fernandez-Serra, A | 1 |
| Ruiz-Simon, A | 1 |
| Gavila, J | 1 |
| Climent, MA | 1 |
| Almenar, S | 1 |
| Cervera-Deval, J | 1 |
| Campos, J | 1 |
| Albaladejo, CV | 1 |
| Llombart-Bosch, A | 1 |
| Guillem, V | 1 |
| Lopez-Guerrero, JA | 1 |
| Guiu, S | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Arnould, L | 1 |
| Fumoleau, P | 1 |
| Park, IH | 2 |
| Ro, J | 2 |
| Lee, KS | 2 |
| Kim, EA | 1 |
| Kwon, Y | 1 |
| Nam, BH | 2 |
| Jung, SY | 1 |
| Lee, S | 1 |
| Kim, SW | 1 |
| Kang, HS | 1 |
| Lee, YS | 1 |
| Kim, SY | 1 |
| Hong, SH | 1 |
| Jeong, J | 1 |
| Lee, H | 1 |
| Osborn, G | 1 |
| Jones, M | 1 |
| Champ, C | 1 |
| Gower-Thomas, K | 1 |
| Vaughan-Williams, E | 1 |
| Wink, CJ | 1 |
| Woensdregt, K | 1 |
| Nieuwenhuijzen, GA | 1 |
| van der Sangen, MJ | 1 |
| Hutschemaekers, S | 1 |
| Roukema, JA | 1 |
| Tjan-Heijnen, VC | 1 |
| Voogd, AC | 1 |
| Correa, PD | 1 |
| Shrimali, RK | 1 |
| Han, S | 1 |
| Rizwanullah, M | 1 |
| Riemsma, R | 1 |
| Forbes, CA | 1 |
| Amonkar, MM | 1 |
| Lykopoulos, K | 1 |
| Diaz, JR | 1 |
| Kleijnen, J | 1 |
| Rea, DW | 1 |
| Langoi, D | 1 |
| Pavone, ME | 1 |
| Gurates, B | 1 |
| Chai, D | 1 |
| Fazleabas, A | 1 |
| Bulun, SE | 1 |
| Glück, S | 1 |
| von Minckwitz, G | 1 |
| Untch, M | 1 |
| Bowman, A | 1 |
| Gabra, H | 1 |
| Langdon, SP | 1 |
| Lessells, A | 1 |
| Stewart, M | 1 |
| Young, A | 1 |
| Smyth, JF | 1 |
| Tominaga, T | 1 |
| Adachi, I | 1 |
| Sasaki, Y | 1 |
| Tabei, T | 1 |
| Ikeda, T | 1 |
| Takatsuka, Y | 1 |
| Toi, M | 1 |
| Suwa, T | 1 |
| Ohashi, Y | 1 |
| Vergote, I | 1 |
| Robertson, JF | 1 |
| Kleeberg, U | 1 |
| Burton, G | 1 |
| Osborne, CK | 1 |
| Mauriac, L | 2 |
| Ellis, MJ | 2 |
| Long, BJ | 2 |
| Jelovac, D | 2 |
| Handratta, V | 2 |
| Thiantanawat, A | 1 |
| MacPherson, N | 1 |
| Ragaz, J | 1 |
| Goloubeva, OG | 2 |
| Brodie, AM | 2 |
| Mouridsen, H | 1 |
| Chaudri-Ross, HA | 2 |
| Macedo, L | 1 |
| Ingle, JN | 1 |
| Ansari, TN | 1 |
| Mahmood, A | 1 |
| Hussain, I | 1 |
| Samad, A | 1 |
| Lipton, A | 1 |
| Leitzel, K | 1 |
| Ali, SM | 1 |
| Demers, L | 1 |
| Harvey, HA | 1 |
| Evans, D | 1 |
| Lang, R | 1 |
| Hackl, W | 1 |
| Hamer, P | 1 |
| Carney, W | 1 |
| Bertelli, G | 2 |
| Garrone, O | 2 |
| Bertolotti, L | 2 |
| Occelli, M | 2 |
| Conforti, S | 1 |
| Marzano, N | 1 |
| Febbraro, A | 1 |
| Carlini, P | 2 |
| Liossi, C | 1 |
| Leonard, RC | 2 |
| Merlano, M | 1 |
| Castiglione, F | 1 |
| Pepi, F | 1 |
| Fusco, O | 1 |
| Alba, E | 1 |
| Llombart, A | 1 |
| Ribelles, N | 1 |
| Ramos, M | 1 |
| Fernández, R | 1 |
| Mayordomo, JI | 1 |
| Tusquets, I | 1 |
| Gil, M | 1 |
| Barnadas, A | 1 |
| Carabante, F | 1 |
| Ruiz, M | 1 |
| Vera, R | 1 |
| Palomero, I | 1 |
| Soriano, V | 1 |
| González, J | 1 |
| Colomer, R | 1 |
| Delea, TE | 1 |
| Karnon, J | 1 |
| Smith, RE | 1 |
| Johnston, SR | 1 |
| Brandman, J | 1 |
| Sung, JC | 1 |
| Gross, PE | 1 |
| Goss, P | 1 |
| Bondarenko, IN | 1 |
| Manikhas, GN | 1 |
| Pendergrass, KB | 1 |
| Miller, WH | 1 |
| Langecker, P | 1 |
| Blanchett, D | 1 |
| Macaskill, EJ | 1 |
| Young, O | 1 |
| Murray, J | 1 |
| Cameron, D | 1 |
| Kerr, GR | 1 |
| Evans, DB | 2 |
| Miller, WR | 2 |
| Ramirez, PT | 1 |
| Schmeler, KM | 1 |
| Milam, MR | 1 |
| Slomovitz, BM | 1 |
| Smith, JA | 1 |
| Kavanagh, JJ | 1 |
| Deavers, M | 1 |
| Levenback, C | 1 |
| Dombernowsky, P | 1 |
| Smith, I | 1 |
| Falkson, G | 1 |
| Leonard, R | 1 |
| Panasci, L | 1 |
| Bellmunt, J | 1 |
| Bezwoda, W | 1 |
| Gardin, G | 1 |
| Gudgeon, A | 1 |
| Morgan, M | 1 |
| Fornasiero, A | 1 |
| Hoffmann, W | 1 |
| Michel, J | 1 |
| Hatschek, T | 1 |
| Tjabbes, T | 1 |
| Chaudri, HA | 2 |
| Hornberger, U | 1 |
| Trunet, PF | 1 |
| Gershanovich, M | 1 |
| Campos, D | 1 |
| Lurie, H | 1 |
| Bonaventura, A | 1 |
| Jeffrey, M | 1 |
| Buzzi, F | 1 |
| Bodrogi, I | 1 |
| Ludwig, H | 1 |
| Reichardt, P | 1 |
| O'Higgins, N | 1 |
| Romieu, G | 1 |
| Friederich, P | 1 |
| Lassus, M | 1 |
| Hamilton, A | 1 |
| Piccart, M | 1 |
| Coop, A | 1 |
| Singh, B | 1 |
| Llombert-Cussac, A | 1 |
| Jänicke, F | 1 |
| Dugan, M | 1 |
| Brady, C | 1 |
| Quebe-Fehling, E | 1 |
| Borgs, M | 1 |
| Cocconi, G | 1 |
| Frassoldati, A | 1 |
| De Marco, S | 1 |
| Casali, A | 1 |
| Ruggeri, EM | 1 |
| Nardi, M | 1 |
| Papaldo, P | 1 |
| Paoloni, F | 1 |
| Cognetti, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole,[NCT00412022] | Phase 3 | 1,294 participants (Actual) | Interventional | 2004-03-31 | Active, not recruiting | ||
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer[NCT03192293] | Phase 2 | 28 participants (Anticipated) | Interventional | 2017-01-20 | Recruiting | ||
| PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32)[NCT04421547] | Phase 3 | 236 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for letrozole and Disease Exacerbation
| Article | Year |
|---|---|
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Fe | 2012 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2013 |
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female | 2004 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
16 trials available for letrozole and Disease Exacerbation
| Article | Year |
|---|---|
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density Conservati | 2019 |
Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2013 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breas | 2015 |
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2010 |
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; C | 2002 |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progres | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2003 |
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2004 |
Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Topics: Administration, Oral; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Disease Progression; Fema | 2005 |
Letrozole in advanced breast cancer: the PO25 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis | 2007 |
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Me | 2007 |
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Disease Progr | 2009 |
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Drug Resistan | 2008 |
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease P | 1998 |
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Topics: Administration, Oral; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Co | 1998 |
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; ErbB Receptors; E | 2001 |
32 other studies available for letrozole and Disease Exacerbation
| Article | Year |
|---|---|
Long-term effect of letrozole on metastatic uterine smooth muscle tumors of uncertain malignant potential: A case report.
Topics: Disease Progression; Doxorubicin; Female; Humans; Letrozole; Lung Neoplasms; Middle Aged; Smooth Mus | 2023 |
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast; Breast Neoplasms; Coho | 2019 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
A joint test for progression and survival with interval-censored data from a cancer clinical trial.
Topics: Antineoplastic Agents; Bias; Breast Neoplasms; Clinical Trials as Topic; Data Interpretation, Statis | 2014 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2015 |
Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis.
Topics: Animals; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Disease Models, Animal; Disease P | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuv | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
Assessing survival benefit when treatment delays disease progression.
Topics: Aromatase Inhibitors; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; | 2016 |
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2016 |
Palbociclib improves survival in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Tri | 2017 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservat | 2017 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2017 |
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2009 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Topics: 3' Untranslated Regions; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Breast Neoplasms | 2010 |
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease Pr | 2010 |
Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Disease Progression; Endometriosis | 2013 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2001 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dis | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line | 2004 |
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Disease Progress | 2005 |
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Dis | 2006 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2006 |
False shortening of time to progression in letrozole 2.5-mg dose?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Re | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopl | 2001 |